1. Introduction
Transthyretin amyloidosis (ATTR) is a form of amyloidosis caused by transthyretin (TTR), broadly classified into the hereditary (ATTRv) and wild-type (ATTRwt) forms [
1]. In ATTRv, clinical manifestations, e.g., familial amyloidotic polyneuropathy and familial amyloid cardiomyopathy, are well recognized [
2,
3]. In contrast, ATTRwt was formerly referred to as senile systemic amyloidosis, and its clinical features have been described accordingly [
4].
Amyloid formation from TTR proceeds via an initial dissociation of the tetrameric structure [
5], and this tetramer dissociation represents the rate-limiting step in pathogenesis, after which the released monomers undergo partial structural denaturation, becoming amyloidogenic [
6]. Ultimately, these monomers aggregate to form amyloid fibrils and amorphous deposits [
7].
In ATTRwt, amyloid deposition in the myocardium leads to impaired diastolic function and progressive congestive heart failure. Clinically, the disease predominantly manifests as diastolic dysfunction, frequently presenting as heart failure with preserved ejection fraction. In addition, carpal tunnel syndrome and spinal stenosis may precede cardiac symptoms [
8].
Based on this pathogenic mechanism, pharmacological agents that stabilize TTR and inhibit the progression of amyloid formation have been approved. A representative drug is tafamidis, which is indicated for ATTRwt cardiomyopathy, ATTRv cardiomyopathy, and early-stage ATTRv polyneuropathy [
1]. However, the treatment cost is substantial. For example, in the United States, the annual cost of tafamidis has been reported to reach approximately
$225,000 [
9]. Thus, long-term continuous therapy can impose significant economic burdens on patients and healthcare insurance systems. Furthermore, no established preventive strategies currently exist for ATTRwt, and knowledge about effective interventions at the presymptomatic stage remains limited. Thus, investigating potential preventive interventions that may contribute to reducing the risk of onset or delay the progression of ATTRwt is important.
Research on dietary interventions designed to prevent ATTRwt is limited. However, a previous study demonstrated that arginine stabilizes the TTR tetramer and that oral supplementation of 5000 mg per day for 5 days increased the TTR tetramer/monomer ratio, suggesting the potential of supplementation as a preventive intervention [
10]. That study suggested that the TTR stabilization mechanism by arginine may involve interactions with aromatic amino acid residues that are abundant in TTR, particularly tryptophan.
Furthermore, although specifically targeted at disease progression inhibition (rather than ATTRwt prevention), epigallocatechin-3-gallate (EGCG), which is a component of green tea, has been reported to stabilize TTR [
11]. A clinical study demonstrated that daily consumption of 1.5–2 L of green tea over a 12-month period resulted in an approximately 13% reduction in left ventricular myocardial mass [
12]. TTR stabilization by EGCG is attributed to tetramer stabilization via binding at the TTR dimer–dimer interface, which indicates that food-derived compounds can potentially stabilize TTR [
11].
Generally, the degree of pharmacological kinetic stabilization of TTR depends on the fraction of TTR tetramers in which at least one binding site is occupied by a stabilizer [
13]. This fraction is determined by the binding affinity of the stabilizer for TTR, the concentration of albumin, i.e., the major plasma protein competing for binding with TTR, and the plasma concentrations of the stabilizer, TTR, and albumin.
Among these factors, the binding affinity for TTR is considered an important determinant reflecting TTR stabilization capacity. Thus, constructing a model to predict an index related to TTR binding affinity may enable the effective estimation of an index reflecting TTR stabilization capacity. TTR-ANSA displacement activity, based on the displacement of the fluorescent probe 8-anilino-1-naphthalenesulfonic acid (ANSA), has been reported as an indicator of TTR binding affinity [
14].
The exploration of natural compounds with TTR-binding properties has been previously reported [
15]. However, these compounds have primarily been studied for their inhibitory activity against TTR amyloid formation rather than for preventive purposes as food-derived compounds. Food-derived compounds are consumed daily, have high safety profiles, and offer the advantage of long-term intake. ATTRwt is an age-related disease; thus, even compounds with weaker stabilization effects than pharmaceutical agents may contribute to disease prevention through cumulative long-term intake [
16]. From this perspective, the evaluation of food-derived compounds is important. Therefore, developing a computational screening method based on chemical structural information to efficiently identify candidate compounds with TTR stabilization activity in food-derived compounds may be useful.
In this study, we used TTR-ANSA displacement activity as an indicator of TTR binding activity and attempted to construct a model to predict this activity from chemical structural information.
Hypothesis 1: TTR binding activity (%) can be predicted from chemical structural information.
Hypothesis 2: The TTR binding activity score predicted from the chemical structure exhibits a monotonic association with the amyloid fibril formation inhibition rate reported in previous studies under acidic conditions.
By testing these hypotheses, this study aimed to evaluate the utility of a computational screening approach to efficiently identify candidate compounds with TTR stabilization activity from food-derived compounds. In addition, the proposed method was applied to a food compound database for exploratory screening.
Figure 1 shows an overview of the analysis.